These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1167 related items for PubMed ID: 17148679

  • 21. ATP-mediated protein kinase B Akt/mammalian target of rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes improvement of locomotor function after spinal cord injury in rats.
    Hu LY, Sun ZG, Wen YM, Cheng GZ, Wang SL, Zhao HB, Zhang XR.
    Neuroscience; 2010 Sep 01; 169(3):1046-62. PubMed ID: 20678995
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 23. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A, Zang C, Chumduri C, Dörken B, Daniel PT, Scholz CW.
    Int J Cancer; 2013 Oct 15; 133(8):1813-24. PubMed ID: 23580240
    [Abstract] [Full Text] [Related]

  • 24. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D.
    Clin Cancer Res; 2004 Oct 15; 10(20):6779-88. PubMed ID: 15501954
    [Abstract] [Full Text] [Related]

  • 25. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
    Bishop JD, Nien WL, Dauphinee SM, Too CK.
    J Endocrinol; 2006 Aug 15; 190(2):307-12. PubMed ID: 16899564
    [Abstract] [Full Text] [Related]

  • 26. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M, Rowinsky EK.
    Oncogene; 2000 Dec 27; 19(56):6680-6. PubMed ID: 11426655
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
    Markova B, Albers C, Breitenbuecher F, Melo JV, Brümmendorf TH, Heidel F, Lipka D, Duyster J, Huber C, Fischer T.
    Oncogene; 2010 Feb 04; 29(5):739-51. PubMed ID: 19881535
    [Abstract] [Full Text] [Related]

  • 29. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
    Mungamuri SK, Yang X, Thor AD, Somasundaram K.
    Cancer Res; 2006 May 01; 66(9):4715-24. PubMed ID: 16651424
    [Abstract] [Full Text] [Related]

  • 30. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.
    BJU Int; 2012 Dec 01; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G, Siakantaris M, Papadaki T, Papadavid E, Vassilakopoulos TP, Angelopoulou MK, Marinos L, Nikolaou V, Economidi A, Antoniou C, Patsouris E, Korkolopoulou P.
    J Am Acad Dermatol; 2013 Sep 01; 69(3):375-84. PubMed ID: 23685026
    [Abstract] [Full Text] [Related]

  • 38. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
    Setsu N, Kohashi K, Fushimi F, Endo M, Yamamoto H, Takahashi Y, Yamada Y, Ishii T, Yokoyama K, Iwamoto Y, Oda Y.
    Cancer; 2013 Oct 01; 119(19):3504-13. PubMed ID: 23861137
    [Abstract] [Full Text] [Related]

  • 39. Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells.
    Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG.
    J Biol Chem; 2004 Jan 09; 279(2):1010-9. PubMed ID: 14581487
    [Abstract] [Full Text] [Related]

  • 40. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
    Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Fu H, Khuri FR, Sun SY.
    Mol Cell Biol; 2007 Nov 09; 27(21):7405-13. PubMed ID: 17724079
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 59.